Mayo Clinic Receives Patent for New Treatment of Chronic Sinus Infection

Mayo Clinic yesterday received broad patent coverage for a new treatment of chronic rhinosinusitis (CRS), commonly called “sinus infection,” a disease that annually affects 32 million adults in the United States and currently has no Food and Drug Administration-approved treatment. Studies at Mayo Clinic have found the cause of CRS — a reaction to certain fungi — and demonstrated that the delivery of antifungal drugs directly into the nose and sinuses is safe and significantly reduces patients? symptoms. Improvements in asthma symptoms were noted in the same patient group. Past medical treatments for chronic sinus infections have been unsuccessful or produced severe side effects.

High levels of hormones may reduce asthma severity and improve lung function

Progesterone and estrogen appear to have a positive effect on lung function and reduce the symptoms of asthma, according to a report published by University of Pittsburgh Graduate School of Public Health (GSPH) researchers in the March issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology. “We found that women’s lung function and asthma symptoms improve when estrogen and progesterone levels are raised, both naturally during certain times in the menstrual cycle and with the administration of oral contraceptives or hormone replacement therapy,” said one of the study’s lead researchers.